New therapy offers hope for patients with limited option
News
Hundreds of genetic links to osteoarthritis unlocked
Study paves the way for personalised therapies for osteoarthritis sufferer
Takeda’s Adcetris receives positive opinion for Hodgkin lymphoma treatment
CHMP recommendation brings new hope for patients
Argenx receives positive CHMP opinion for CIDP treatment
VYVGART could be the first CIDP drug with a novel mechanism in 30 years
Mosaic therapeutics expands pipeline with Astex deal
Cambridge firm in-licenses two oncology programmes
Acoramidis approved for heart condition treatment
MHRA authorises drug for adults with rare heart muscle damage
Genomics study launches to optimise childhood cancer care in Ireland
It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment
UCL researchers launch congenital muscular dystrophy research programme
The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK
Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
FDA approves Click’s digital therapeutic for episodic migraine
More than 37 million adults in the US are affected by migraine
Leqembi approved as first treatment to slow early Alzheimer’s progression
European Commission grants authorisation for Eisai and Biogen therapy
Pepaxti shows effectiveness in heavily pretreated multiple myeloma patients
New real-world data reinforce treatment benefit
New data reinforce daratumumab as standard of care for multiple myeloma
Long-term survival projections suggest improved outcomes for patients
Global data highlights effectiveness of romosozumab
Studies show improved bone mineral density and healthcare cost reductions
UK clinical trials regulations signed into law
Major update aims to accelerate research and strengthen patient safety
